Spots Global Cancer Trial Database for haematologic disease
Every month we try and update this database with for haematologic disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies | NCT04298892 | Haematologic Di... Haematological ... | clinical data a... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation | NCT04180059 | Haematologic Di... | CTL 19 | 18 Years - 75 Years | Nantes University Hospital | |
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | NCT05581875 | Multiple Myelom... Multiple Myelom... Neoplasms Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease Neoplasms, Plas... | Belantamab Mafo... Daratumumab Pomalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies | NCT04298892 | Haematologic Di... Haematological ... | clinical data a... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |